title: A cisplatinum-cyclophosphamide regimen in advanced ovarian cancer: reporting 5-year results.
abstract: The following paper reports the evaluation of 53 consecutive patients with advanced ovarian epithelial carcinoma (FIGO stage III-IV), treated between October 1984 and December 1987 with immediate or delayed cytoreduction surgery and chemotherapy. Combination chemotherapy consisted of cisplatinum 45 mg/m2 i.v. for 2 consecutive days and cyclophosphamide 900 mg/m2 i.v. on the second day, administered every 28 days for a maximum of 8 courses. Objective responses were observed in 35 of 50 evaluable patients (70%), 17 (34%) of whom were pathological complete remissions (pCR). For patients with minimal residual disease before chemotherapy a higher pCR rate was achieved (10/20 vs. 7/30; p = N.S.). Median survival time of all patients was 29 months; subjects with minimal residual disease and good performance status before treatment had higher survival (48 vs. 22 months-p < 0.05 and 29 vs. 9 months-p < 0.05, respectively). Median time to progression was 25 months. After a median follow-up of 60 months, 15 (28%) patients were alive, 14 of whom disease-free. Toxicity was moderate with a particularly low incidence of nephrotoxicity and no case of serious long-lasting neuropathy. These findings suggest that the described combination has an efficacy comparable to other CDDP-containing combinations, using 2, 3 or more drugs, with a low incidence of acute serious toxicities and of disabling delayed sequelae.
authors.affiliation: Division of Medical Oncology, S. Carlo Borromeo Hospital, Milan, Italy.
authors.forename: M C
authors.initials: MC
authors.lastname: Locatelli
authors.forename: A
authors.initials: A
authors.lastname: D'Antona
authors.forename: R
authors.initials: R
authors.lastname: Carcione
authors.forename: B
authors.initials: B
authors.lastname: Cesana
authors.forename: G
authors.initials: G
authors.lastname: Dallavalle
authors.forename: M
authors.initials: M
authors.lastname: Vinci
authors.forename: M
authors.initials: M
authors.lastname: Clerici
authors.forename: R
authors.initials: R
authors.lastname: Labianca
authors.forename: C
authors.initials: C
authors.lastname: Pasquinucci
authors.forename: G
authors.initials: G
authors.lastname: Luporini
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D003520:Cyclophosphamide; D002945:Cisplatin